Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, Mcgill JB, Mcmurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA (2019)


Publication Type: Journal article

Publication year: 2019

Journal

Book Volume: 73

Pages Range: 309-315

Journal Issue: 3

DOI: 10.1053/j.ajkd.2018.10.006

Abstract

Rationale & Objective: Evidence from clinical trials to guide patient preparation for maintenance dialysis therapy is limited. Although anemia is associated with mortality and cardiovascular (CV) disease in individuals initiating maintenance dialysis therapy, it is not known if treatment of anemia before dialysis therapy initiation with erythropoiesis-stimulating agents alters outcomes.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Mc Causland, F.R., Claggett, B., Burdmann, E.A., Chertow, G.M., Cooper, M.E., Eckardt, K.-U.,... Pfeffer, M.A. (2019). Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 73(3), 309-315. https://dx.doi.org/10.1053/j.ajkd.2018.10.006

MLA:

Mc Causland, Finnian R., et al. "Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)." American Journal of Kidney Diseases 73.3 (2019): 309-315.

BibTeX: Download